Agilent/$A
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Agilent
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
- Ticker
- $A
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 18,200
- Headquarters
- Santa Clara, United States
- Website
- www.agilent.com
Agilent Metrics
BasicAdvanced
$49B
34.48
$5.07
1.24
$1.02
0.58%
Price and volume
Market cap
$49B
Beta
1.24
52-week high
$182.99
52-week low
$108.35
Average daily volume
2.3M
Dividend rate
$1.02
Financial strength
Current ratio
2.05
Quick ratio
1.414
Long term debt to equity
0.495
Total debt to equity
0.536
Dividend payout ratio (TTM)
19.86%
Interest coverage (TTM)
17.07%
Profitability
EBITDA (TTM)
2,080
Gross margin (TTM)
53.65%
Net profit margin (TTM)
19.53%
Operating margin (TTM)
24.80%
Effective tax rate (TTM)
13.15%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
8.72%
Return on equity (TTM)
20.97%
Valuation
Price to earnings (TTM)
34.479
Price to revenue (TTM)
6.701
Price to book
6.7
Price to tangible book (TTM)
34.55
Price to free cash flow (TTM)
38.99
Free cash flow yield (TTM)
2.56%
Free cash flow per share (TTM)
4.485
Dividend yield (TTM)
0.58%
Forward dividend yield
0.58%
Growth
Revenue change (TTM)
8.60%
Earnings per share change (TTM)
18.40%
3-year revenue growth (CAGR)
1.77%
10-year revenue growth (CAGR)
5.98%
3-year earnings per share growth (CAGR)
9.87%
10-year earnings per share growth (CAGR)
13.40%
3-year dividend per share growth (CAGR)
4.61%
10-year dividend per share growth (CAGR)
8.57%
What the Analysts think about Agilent
Analyst ratings (Buy, Hold, Sell) for Agilent stock.
Analyst projections of the future price of Agilent stock.
Bulls say / Bears say
Third-quarter core revenue rose 7.3%, and Agilent raised its full-year core growth and earnings outlook. That points to improving demand and gives the company a stronger near-term growth base. (Agilent)
Recent instrument launches are gaining traction: the 9500 ICP-MS sales funnel exceeded $60 million, while early orders for new flagship gas chromatographs were more than twice expectations. If demand holds, these products could support further growth beyond the latest quarter. (The Motley Fool)
Agilent’s proposed acquisition of Proscia would add a digital pathology platform with an established laboratory and pharmaceutical customer base. Its recurring-revenue software could broaden Agilent’s pathology offering and add a new source of growth, though the deal is not yet complete. (Agilent)
Tariff refunds contributed $0.06 to Q3 adjusted EPS and about 110 basis points to its non-GAAP operating margin, so headline earnings and margin growth overstate the quarter’s recurring improvement. The company also flags uncertainty over further refunds and ongoing geopolitical and supply-chain cost risks. (Agilent, SEC)
Academic and government revenue fell 3% in Q3, and Agilent had previously reported that tighter or delayed government spending weighed on these customers and food testing. Further funding delays could hold back demand in these more exposed markets. (The Motley Fool, The Motley Fool)
Agilent expects Advanced Therapeutics to be roughly flat in Q4 after strong growth, citing a difficult comparison and the timing of customers’ regulatory submissions. That leaves an important growth driver vulnerable to delays outside Agilent’s control. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 21 Oct 2026.
Agilent Financial Performance
Revenues and expenses
Agilent Earnings Performance
Company profitability
Upcoming events
No upcoming events
Agilent News
AllArticlesVideos
Funds containing Agilent
AllUSDEURGBP
Fund name | Fund size | $A weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 1.50% |
iShares Healthcare Innovation€2B78 | $1.2B | 1.50% |
iShares Healthcare Innovation$HEAL | $1.3B | 1.50% |
VanEck Morningstar Wide Moat$MOAT | $396M | 1.47% |
VanEck Morningstar Wide Moat€GMVM | $376M | 1.47% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.